ProShare Advisors
EGRX

ProShare Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

ProShare Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,674
Closed -$238K – 2322
2021
Q4 		$238K Buy
4,674
+90
+2% +$4.66K ﹤0.01% 1923
2021
Q3 		$256K Sell
4,584
-1,102
-19% -$54.2K ﹤0.01% 1665
2021
Q2 		$243K Buy
5,686
+768
+16% +$31.7K ﹤0.01% 2026
2021
Q1 		$205K Buy
4,918
+383
+8% +$17.8K ﹤0.01% 2028
2020
Q4 		$211K Buy
+4,535
New +$212K ﹤0.01% 1821
2020
Q1 		– Sell
-4,468
Closed -$268K – 1645
2019
Q4 		$268K Sell
4,468
-525
-11% -$31.3K ﹤0.01% 1411
2019
Q3 		$282K Sell
4,993
-485
-9% -$27.3K ﹤0.01% 1262
2019
Q2 		$305K Sell
5,478
-701
-11% -$36.6K ﹤0.01% 1232
2019
Q1 		$312K Sell
6,179
-298
-5% -$13.3K ﹤0.01% 1236
2018
Q4 		$261K Sell
6,477
-1,237
-16% -$63.7K ﹤0.01% 1229
2018
Q3 		$535K Sell
7,714
-164
-2% -$12.4K ﹤0.01% 1078
2018
Q2 		$596K Sell
7,878
-279
-3% -$17.6K ﹤0.01% 1036
2018
Q1 		$430K Sell
8,157
-1,329
-14% -$77.3K ﹤0.01% 1164
2017
Q4 		$507K Buy
9,486
+211
+2% +$11.7K ﹤0.01% 1125
2017
Q3 		$553K Buy
9,275
+577
+7% +$34.9K 0.01% 919
2017
Q2 		$686K Sell
8,698
-749
-8% -$61.3K 0.01% 846
2017
Q1 		$784K Sell
9,447
-2,348
-20% -$175K 0.01% 839
2016
Q4 		$936K Buy
11,795
+902
+8% +$65.5K 0.01% 806
2016
Q3 		$763K Sell
10,893
-1,830
-14% -$101K 0.01% 769
2016
Q2 		$494K Buy
12,723
+97
+0.8% +$4.04K 0.01% 970
2016
Q1 		$511K Sell
12,626
-1,160
-8% -$73.6K 0.01% 979
2015
Q4 		$1.22M Buy
+13,786
New +$1.09M 0.01% 664

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

ProShare Advisors's EGRX Position: Q1 2022 in Review

ProShare Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 4,674 shares — an estimated $238K sold.

ProShare Advisors first reported a position in EGRX in Q4 2015 and held it in 22 quarters. The position peaked at $1.22M in Q4 2015. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • ProShare Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 4,674 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $238K.
  • ProShare Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 22 quarters.
  • ProShare Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.22M in Q4 2015.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.